FDA advisory committee votes again higher dose of Lilly-Incyte arthritis drug

Apr 24, 2018

Developed by Eli Lilly and Incyte, rheumatoid arthritis drug baricitinib suffered a setback as an advisory committee to the U.S. Food and Drug Administration voted against approval of a 4-milligram dose. The committee did however vote in favor of approving a lower, 2 milligram (mg) dose.

The vote came a year after baricitinib was already rejected by the FDA, citing safety concerns.

Read the Retuers report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments